A comparison of single-target GLP-1 agonism versus dual GIP/GLP-1 receptor engagement. Both compounds are studied for metabolic pathway modulation but differ fundamentally in receptor pharmacology.
| Criterion | ||
|---|---|---|
| Receptor Target | GLP-1R only | GLP-1R + GIPR (dual agonist) |
| Molecular Weight | 4113.58 g/mol | 4813.45 g/mol |
| Mechanism | cAMP/PKA via GLP-1R | Dual incretin cascade with GIP potentiation |
| Half-life Extension | C18 fatty diacid → albumin binding | C20 fatty diacid → albumin binding |
| Research Applications | Incretin signaling, gastric motility | Dual receptor crosstalk, lipid metabolism |
| Price (5 mg) | $69.00 | $109.00 |
Purchase These Compounds
Research Assessment
Semaglutide is the established benchmark for GLP-1R-specific research. Tirzepatide adds GIP receptor engagement for studies requiring dual incretin pathway investigation. The choice depends on whether single- or dual-receptor pharmacology is needed for the research model.
View Products
Research Profiles
More Comparisons
Quick Reference
Related Research & Documentation
